Last updated: May 15, 2026
Sotradecol (sodium tetradecyl sulfate) remains a niche, procedure-linked injectable sclerosant used for endovenous treatment of varicose veins (and related venous insufficiency indications). Clinical trial activity and near-term market growth are constrained by (1) a mature, clinician-administered use pattern, (2) relatively limited pipeline expansion versus large chronic-care markets, and (3) the drug’s dependency on periodic demand cycles tied to elective procedure volumes. Patent and regulatory exclusivity characteristics must be assessed per listed Orange Book entries to quantify generic and compounding entry risk and the timing of potential nonpatent exclusivity lapses.
What is SOTRADECOL (sodium tetradecyl sulfate) used for, and what clinical endpoints matter?
Featured snippet answer: Sotradecol is an injectable sclerosant (sodium tetradecyl sulfate) used to treat varicose veins and related venous disorders using catheter or injection-based sclerotherapy. Trials and adoption metrics typically track procedural success, vein closure or symptom improvement, and safety outcomes such as local reactions and thromboembolic events.
Indication framing and trial endpoints
Clinical development and postmarketing evidence for sclerosants usually centers on:
- Efficacy: treated-vein closure, reduction in vein diameter or Venous Clinical Severity Score (VCSS), symptom improvement, or absence of clinically significant residual reflux.
- Durability: recurrence or re-treatment rates at 6 to 24 months.
- Safety: injection-site pain, hyperpigmentation, ulceration, allergic reactions, transient visual disturbances (rare), and thrombotic/embolism-related events.
Dosage form and administration considerations
Sotradecol is administered intravascularly by clinicians. Key variables affecting trial comparability and real-world performance include:
- Concentration used and volume per treatment session
- Treatment strategy (single-session vs staged)
- Guidance method (ultrasound guidance vs landmark-based)
- Patient selection (vein size, tortuosity, CEAP class)
What is the latest clinical trials update for SOTRADECOL?
Featured snippet answer: No current, high-profile phase 3 development program for Sotradecol is evident at the level typically reflected by major endpoint registration activity in public trial registries during the most recent windows. Most activity is expected to sit in label maintenance, postmarketing studies, comparability work, or procedure-optimization research rather than standalone late-stage pivots.
What “update” usually means for mature injectables like Sotradecol
For mature sclerosants, the practical clinical “update” tends to include:
- Post-approval protocol updates for administration technique
- Observational cohorts and real-world outcomes datasets
- Head-to-head or comparative effectiveness studies against alternative techniques (thermal ablation, mechanochemical ablation, or other sclerosants)
- Stability or manufacturing comparability work that can inform supply reliability rather than efficacy expansion
Where to look for meaningful signal
For procedure-linked generics and branded injectables, trial relevance usually hinges on:
- Whether endpoints map to guideline endpoints (symptom relief and closure)
- Whether the comparator is clinically used in parallel (other sclerosants or ablation modalities)
- Whether results translate into treatment protocols adopted by vein clinics
How big is the SotradeCOL market, and what drives demand?
Featured snippet answer: Sotradecol participates in the varicose veins treatment market where demand tracks elective volume, reimbursement behavior, and adoption of minimally invasive venous procedures. Branded share is pressured by generic availability, compounding, and substitution within sclerosant classes and against other procedure modalities.
Demand drivers
- Elective procedure volumes: office-based sclerotherapy uptake rises and falls with healthcare utilization patterns.
- Clinical preference and workflow fit: sclerosants remain competitive for spider veins and select segments where ablation techniques are less favored.
- Reimbursement: coverage and coding patterns influence clinician adoption.
- Supply reliability: injectable products with supply constraints can shift usage to substitutes even when efficacy is comparable.
Market structure and competitive substitution
Sotradecol competes across:
- Other sclerosants (polidocanol, hypertonic saline, and different sodium formulations)
- Thermal ablation and non-thermal alternatives (laser/RF ablation, mechanochemical ablation)
- Office procedural substitution: when practices shift technique mix, sclerosant volumes can contract
What market share does Sotradecol have, and how should it be modeled?
Featured snippet answer: Because Sotradecol is an older niche injectable with limited public, branded-specific market-share disclosure, projection modeling typically uses demand drivers rather than relying on reported brand sales share. The right approach is scenario modeling: procedure volumes times penetration of sclerosant-based care times branded vs generic allocation.
Projection model structure (scenario-driven)
A defensible market projection for Sotradecol typically uses:
- Total addressable market: treated varicose veins volume (or procedure counts)
- Technique share: proportion treated with sclerosants vs ablation modalities
- Sclerosant mix: sodium tetradecyl sulfate share within sclerosants
- Brand allocation: branded vs generic substitution rates
- Supply and inventory effects: short-term substitution due to availability
Sensitivities
- Procedure reimbursement changes can swing technique share.
- Competitor product availability can shift sodium tetradecyl sulfate demand.
- Clinician guideline changes and device adoption (ablation penetration) can reduce sclerosant share.
- Generic entry can reduce branded allocation materially and quickly after launch.
When does SotradeCOL lose exclusivity, and what patents govern the product?
Featured snippet answer: Exclusivity and patent protection for Sotradecol must be derived from the Orange Book patent listings tied to the specific NDC and dosage strengths. Patent expiration and regulatory exclusivity are product-specific and must be checked against each listed U.S. patent number.
How to map Sotradecol exclusivity properly
An exclusivity timeline requires:
- Orange Book listings for each strength and dosage form
- Patent categories: drug substance, drug product, method of use, and whether patents are “listed” vs “expired”
- Whether any 5-year new chemical entity (NCE), 3-year new clinical investigation, or 7-year orphan exclusivity applies (often not applicable for older sclerosants)
- Exclusivity termination due to generic approvals, if applicable
Patent estate categories that matter commercially
For procedure-linked injectables, the most commercially relevant patents are usually:
- Formulation or stabilization patents affecting shelf-life and injection tolerability
- Device or method-of-use patents tied to treatment protocols
- Manufacturing method patents that constrain generic manufacturing and dilution/refill processes
What is the Orange Book status of SotradeCOL?
Featured snippet answer: The Orange Book status must be confirmed per NDC. Without an explicit Orange Book listing table for Sotradecol in this feed, the only correct conclusion is that the status cannot be stated precisely here.
What the Orange Book table should include in a diligence pack
- NDA number and dosage form/strength
- Listed patents with expiration dates
- Patent submission dates and listed exclusivity codes
- Protein-binding and FDA application type are not relevant; route is injectable
How strong is the patent estate for SotradeCOL, and which claims are most vulnerable?
Featured snippet answer: For older injectable sclerosants, the patent estate often narrows over time, leaving fewer active claims that can block true generic competition. The highest fragility usually sits in formulation and process claims that can be designed around, and method-of-use claims that are hard to enforce if generics do not induce infringement through labeling.
Typical claim vulnerabilities for branded sclerosants
- Process patents: generic can switch to a different manufacturing route if not tightly constrained.
- Formulation patents: generic can match active and excipients with different stabilization approaches.
- Method-of-use patents: requires label infringement theories or “carve-out” proving induced infringement by clinicians.
Are there Paragraph IV challenges for SotradeCOL, and who filed?
Featured snippet answer: Paragraph IV filings require item-level data from FDA’s Hatch-Waxman litigation reporting and docketing sources. Without a specific, itemized listing in this feed, no reliable statement about who filed, when, and which patents are targeted can be made.
What matters in Paragraph IV for market timing
- The “skinny label” scope
- The specific patent numbers challenged
- The likely settlement date affecting launch
- Whether the generic is ready-to-launch at risk or delayed
What generic entry risks exist for SotradeCOL?
Featured snippet answer: Generic entry risk for Sotradecol depends on the active patent list for the specific NDC and whether any unexpired exclusivity applies. For older injectables, the risk is usually driven by remaining formulation/process patents and any method-of-use protections.
Launch barriers that can delay generics
- In-process validation differences required for equivalent quality
- Stability constraints for sodium tetradecyl sulfate solutions
- Labeling and method-of-use carve-outs
- Litigation or settlements that impose launch delays
How do biosimilars or follow-on biologics apply to SotradeCOL?
Featured snippet answer: Biosimilar frameworks do not apply. Sotradecol is a small-molecule injectable sclerosant, not a biologic product.
What litigation affects SotradeCOL, and what settlement terms are typical?
Featured snippet answer: Litigation status is tied to specific U.S. patent numbers and FDA approval events. Without a docket-level listing of filings and outcomes for Sotradecol in this feed, litigation timing cannot be stated.
Typical settlement outcomes that matter
- 180-day exclusivity to first-filer generics
- Covenant-not-to-sue until a date tied to patent expiration
- Design-around commitments
- Non-monetary agreements about labeling or distribution channels
What commercialization timeline should investors use for SotradeCOL?
Featured snippet answer: Use a regulatory-patent calendar anchored to the Orange Book patent expirations for each Sotradecol NDC and the elapsed procedure-volume assumptions for varicose vein treatment. Branded decline often accelerates after generic availability unless supply constraints or formulation differentiation preserve a residual premium.
Planning calendar structure
- Phase 1: Map active Orange Book patents by NDC to expiration dates
- Phase 2: Identify generic readiness and likely earliest eligible launch date under Hatch-Waxman
- Phase 3: Overlay procedure volume growth and technique-share assumptions
- Phase 4: Model price erosion and branded share decline post-entry
How does SotradeCOL compare with other sclerosants and venous procedures?
Featured snippet answer: Sotradecol’s competitive set spans other sclerosants (notably polidocanol-based products) and non-sclerosant procedures (thermal ablation, mechanochemical ablation). Competition is driven by clinician preference, vein anatomy fit, guideline treatment pathways, and product availability.
Comparative decision factors in practice
- Vein size and anatomy
- Side-effect profiles and clinician comfort
- Treatment session count and re-treatment rates
- Cost per treated course and reimbursement coding
Key Takeaways
- Sotradecol is a mature, procedure-linked injectable sclerosant; clinical development intensity is typically limited to label maintenance, protocol optimization, and real-world outcome work.
- Market outlook is driven by elective venous procedure volumes and technique mix (sclerosants vs ablation), not by blockbuster-style pipeline catalysts.
- Patent and exclusivity risk must be assessed directly from Orange Book listings per NDC; generic entry timing is primarily a function of remaining active patents and any exclusivity terms tied to the NDA.
- Model commercialization using scenario-based assumptions: procedure volumes, sclerosant penetration, branded allocation, and post-generic price erosion.
FAQs
- What NDC-specific patents determine Sotradecol generic entry timing?
- How do clinician technique preferences shift demand between sclerosants and thermal ablation?
- What endpoints best predict durability for sclerosant treatments in varicose vein trials?
- Does Sotradecol face supply-driven substitution risk in vein clinics?
- How should investors model price erosion and branded share loss after generic launch of older injectables like sodium tetradecyl sulfate?
References
- FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. FDA. (Accessed 2026).
- FDA Paragraph IV Notice and Certification records and Hatch-Waxman litigation reporting databases. U.S. FDA. (Accessed 2026).
